VIROCYT LLC RAISES CAPITAL AND BEGINS OPERATIONS
DENVER, Colorado – January 15, 2013 – ViroCyt LLC, a privately-held life science company, announced today that it had begun operations. Concurrent with the formation of ViroCyt, the company secured funding from a group of investors led by High Country Venture, a Colorado Venture Capital Fund. ViroCyt will be responsible for expanding the commercial market for the Virus Counter 2100, a technology originally developed by InDevR, Inc. The Virus Counter provides rapid quantification of viruses, resulting in faster, more accurate decision-making in settings that utilize viruses to create lifesaving products, such as viral vaccine production, protein expression, antiviral drug development, viral diagnostics, and other emerging applications.
“Within the life science research, pharmaceutical and vaccine markets, there is a large and growing need for rapid quantification of viruses, so I am excited to be part of the formation of ViroCyt” stated Robert Kline, President and CEO. “The Virus Counter represents breakthrough technology in this important field and the early customer acceptance has exceeded all expectations.” Examples of organizations currently utilizing the Virus Counter include top global vaccine companies, biotechnologies, domestic and foreign government research institutes and universities.
According to Mark Lupa, Managing Director at High Country Venture, “The recently raised growth capital will be used primarily to build out ViroCyt’s North American sales force, where it sells products directly, as well as expand its international network of distributors in order to recognize the growing global demand for rapid virus quantification technology. The opportunity to form a company around commercialization of the Virus Counter represents a unique investment opportunity.”
“We are tremendously enthusiastic about transitioning the Virus Counter technology to ViroCyt LLC said Dr. Kathy Rowlen, co-founder and CEO at InDevR. With Robert Kline’s demonstrated success in building companies focused on customer satisfaction and meeting market demands, I am confident that the Virus Counter can significantly improve vaccine production as well as positively impact a number of other virus-related industries.”
About ViroCyt, LLC
ViroCyt LLC was created in late 2012 to focus on the commercialization of novel technologies that enable rapid quantification of viruses, such as the Virus Counter 2100. The Company’s mission is to provide the tools that deliver meaningful improvements to critical biotechnology processes such as vaccine manufacturing, protein expression, antiviral development and other settings where viruses play a significant role. To learn more about ViroCyt, go to http://www.virocyt.com.
About High Country Venture, LLC
High Country Venture manages Colorado Funds I & II, venture capital funds that invest in seed and early stage businesses in Colorado. The Fund focuses on the life sciences, information technology, retail and consumer goods sectors. High Country Venture is located in Boulder, Colorado.
Source: ViroCyt, LLC